Suppr超能文献

[肺癌中DNA损伤修复与顺铂耐药机制的研究进展]

[Advances of DNA damage repair and Cisplatin resistance mechanisms in lung cancer].

作者信息

Tang Chunlan, Yang Heping, Zhou Xiangdong

机构信息

Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2011 Dec;14(12):960-4. doi: 10.3779/j.issn.1009-3419.2011.12.11.

Abstract

Lung cancer is the most common cause of death from cancer worldwide per year. Platinum-based combination chemotherapy is a main treatment of lung cancer. Cisplatin is adopted widely and used effectively in the first-line chemotherapy. Unfortunately, development of cisplatin resistance is a major obstacle to the success of lung caner. Cisplatin is a cell-cycle-non-specific cytotoxic drugs and its main target is DNA. Thus, defective DNA damage repair is one of the main mechanisms of cisplatin resistance. In this review, we will focus on the defective DNA damage repair in cisplatin resistance of lung cancer including nucleotide excision repair, DNA mismatch repair, DNA double-strand break repair and translesion synthesis.

摘要

肺癌是全球每年因癌症死亡的最常见原因。铂类联合化疗是肺癌的主要治疗方法。顺铂在一线化疗中被广泛采用且效果良好。不幸的是,顺铂耐药的产生是肺癌治疗成功的主要障碍。顺铂是一种细胞周期非特异性细胞毒性药物,其主要靶点是DNA。因此,DNA损伤修复缺陷是顺铂耐药的主要机制之一。在这篇综述中,我们将聚焦于肺癌顺铂耐药中DNA损伤修复缺陷,包括核苷酸切除修复、DNA错配修复、DNA双链断裂修复和跨损伤合成。

相似文献

1
[Advances of DNA damage repair and Cisplatin resistance mechanisms in lung cancer].
Zhongguo Fei Ai Za Zhi. 2011 Dec;14(12):960-4. doi: 10.3779/j.issn.1009-3419.2011.12.11.
2
The role of DNA repair pathways in cisplatin resistant lung cancer.
Cancer Treat Rev. 2014 Dec;40(10):1161-70. doi: 10.1016/j.ctrv.2014.10.003. Epub 2014 Oct 18.
3
ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3). doi: 10.1073/pnas.2015808118.
5
NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
Int J Biochem Cell Biol. 2018 Jul;100:54-60. doi: 10.1016/j.biocel.2018.05.003. Epub 2018 May 26.
7
DNA repair pathways and cisplatin resistance: an intimate relationship.
Clinics (Sao Paulo). 2018 Sep 6;73(suppl 1):e478s. doi: 10.6061/clinics/2018/e478s.
9
FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.
Mol Oncol. 2017 Jun;11(6):640-654. doi: 10.1002/1878-0261.12058. Epub 2017 May 12.

引用本文的文献

1
Development of a prognostic model for NSCLC based on differential genes in tumour stem cells.
Sci Rep. 2024 Sep 9;14(1):20938. doi: 10.1038/s41598-024-71317-2.
4
Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma.
Cancers (Basel). 2022 Sep 9;14(18):4395. doi: 10.3390/cancers14184395.
5
Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.
MedComm (2020). 2021 Jun 10;2(3):315-340. doi: 10.1002/mco2.55. eCollection 2021 Sep.
6
[ole of AGGF1 in DNA damage repair and modulating chemotherapy resistance in human colon cancer cells ].
Nan Fang Yi Ke Da Xue Xue Bao. 2018 Jul 30;38(7):861-866. doi: 10.3969/j.issn.1673-4254.2018.07.15.
7
Pharmacological Effects of Verticine: Current Status.
Evid Based Complement Alternat Med. 2019 Mar 7;2019:2394605. doi: 10.1155/2019/2394605. eCollection 2019.

本文引用的文献

1
Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Cancer Chemother Pharmacol. 2011 Jun;67(6):1389-400. doi: 10.1007/s00280-010-1435-5. Epub 2010 Aug 31.
2
The treatment of early-stage disease.
Semin Radiat Oncol. 2010 Jul;20(3):178-85. doi: 10.1016/j.semradonc.2010.01.004.
3
Cisplatin resistance: preclinical findings and clinical implications.
Biochim Biophys Acta. 2010 Dec;1806(2):172-82. doi: 10.1016/j.bbcan.2010.07.004. Epub 2010 Jul 17.
4
Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients.
Acta Biochim Biophys Sin (Shanghai). 2010 May 15;42(5):311-7. doi: 10.1093/abbs/gmq023.
5
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
DNA Repair (Amst). 2010 Jul 1;9(7):745-53. doi: 10.1016/j.dnarep.2010.03.010. Epub 2010 Apr 24.
8
[ERCC1 and RRM1 genes in lung cancer].
Rev Port Pneumol. 2009 Jul-Aug;15(4):683-96. doi: 10.1016/s0873-2159(15)30164-1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验